Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Arkansas
About this trial
By doing this study, it is the hope to learn whether an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) into the tumor is safe and effective in making the tumor smaller.
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Pathologically proven locally advanced adenocarcinoma of pancreas.
Encasement of gastroduodenal artery up to the common hepatic artery/short segment encasement or abutment of the hepatic artery, but without extension to the celiac trunk.
Venous involvement of SMV or portal vein, less than 180 degrees.
Disqualifiers
Pancreatic cancer that was either resectable before SoC treatment or became resectable following SoC chemotherapy and RT.
Subjects with radiographically proven metastatic disease are excluded.
Subject must not be pregnant and/or currently breastfeeding or plan to be.
Subject must not have received any live vaccine, including MMR, within 30 days prior to the dose of study drug.
Trial design
Treatments tested in this trial
- Intratumoral MMR Injection
Treatment groups
20 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov